NASDAQ · STOCK
Regeneron Pharmaceuticals
$762.72
52W $541.00 – $821.11
60/100
$78.57B
18.2
0.24
Is REGN Bullish or Bearish?
Bullish.
Innellis AI committee rates Regeneron Pharmaceuticals (REGN) Buy with a composite score of 60/100
, based on 7 analysts with 57% agreement.
Last updated July 31, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +15.24 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -4.76 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull & Bear Case
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Low leverage (debt-to-equity 0.09) -- balance sheet can absorb a shock — Risk
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- RSI at 84 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of July 31, 2026
Overall Committee Score
60/100
Agreement
57%
Analysts
7
Conviction
Contested
Sector Rank
Top 11%
of 93 Healthcare peers
Value Analyst
bullish
62
/ 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
Growth Analyst
bullish
68
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ 5 consecutive earnings beats -- consistent execution
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− RSI at 84 is in overbought territory
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.09) -- balance sheet can absorb a shock
Macro Analyst
neutral
58
/ 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Investment Thesis Evolution
Committee score moved marginally from 59.4 to 59.8.
- New bearish signals: 4 appeared.
- Bullish support removed: 2 signal(s) disappeared.
- New bullish signals: 3 appeared.
- Bearish pressure eased: 4 signal(s) disappeared.
- Analyst(s) changed stance: Growth Analyst, Macro Analyst, News Analyst.
Analyst-level changes:
- Growth Analyst: stance neutral->bullish; score 52->68 (+17); +2 bullish signal(s).
- Macro Analyst: stance bullish->neutral; score 65->58 (-8); +1 bullish signal(s).
- News Analyst: stance bullish->neutral; score 64->58 (-6).
- Portfolio Manager: +2 bearish signal(s).
- Technical Analyst: +2 bearish signal(s).
Comparing 2026-07-30 to 2026-07-31 (1 day apart).
Technical Analysis
RSI (14)
87.1
Overbought
MACD Histogram
8.865
Bullish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Mixed
Support
$728.73
Resistance
$814.64
Bollinger %B
1.25
Above Upper Band
Price vs Moving Averages
EMA 9
$702.26
Above
EMA 21
$678.51
Above
EMA 50
$668.68
Above
EMA 200
$688.47
Above
Fundamental Analysis
Valuation
29
Growth
79
Profitability
1
Financial Health
100
Cash Flow
37
Valuation
P/E Ratio
18.2×
P/B Ratio
—
PEG Ratio
58.48
Dividend Yield
0.00%
52W High
$821.11
52W Low
$541.00
Quality & Growth
ROE
14.4%
ROA
11.1%
Gross Margin
83.4%
Operating Margin
24.7%
Revenue Growth YoY
—
Debt / Equity
0.06
AI Fundamental Assessment
P/E ratio of 18.2 (inexpensive relative to a 15-40x range); Price-to-book of 2486674.9x; PEG ratio of 58.5 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.1%; Return on assets of 0.1%; Net margin of 0.3%; Gross margin of 0.8%; Current ratio of 3.34 (healthy short-term liquidity); Debt-to-equity of 0.06; Free cash flow margin of 0.8% (thin cash generation); Free cash flow per share is positive (34.06); Most recent quarter beat estimates by 36.5%; 5 consecutive earnings beats; EPS growth accelerating (-17.2% -> +50.9% QoQ); Average YoY EPS growth of 10.9%; Analyst estimates falling over recent quarters
Get the Full REGN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →